Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule

Journal of Immunological Methods

Volumn 338, Issue 1-2, 2008, Pages 1-6

  Vernet, Erik ^a   Konrad, Anna ^a   Lundberg, Emma ^a   Nygren, Per Åke ^a   Gräslund, Torbjörn ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Affibody molecule; Endoplasmic reticulum; ErbB2; Flow cytometry; HER2

Indexed keywords

AFFIBODY MOLECULE; CELL EXTRACT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ER RETENTION PEPTIDE EXTENSION; HYBRID PROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 50949094371     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.06.005     Document Type: Article

References (35)

1. Alvarez R.D., Barnes M.N., Gomez-Navarro J., Wang M., Strong T.V., Arafat W., Arani R.B., Johnson M.R., Roberts B.L., Siegal G.P., and Curiel D.T. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6 (2000) 3081
2. Beerli R.R., Wels W., and Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269 (1994) 23931
3. Binz H.K., and Pluckthun A. Engineered proteins as specific binding reagents. Curr. Opin. Biotechnol. 16 (2005) 459
4. Binz H.K., Amstutz P., and Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23 (2005) 1257
5. Choudhury A., Charo J., Parapuram S.K., Hunt R.C., Hunt D.M., Seliger B., and Kiessling R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer 108 (2004) 71
6. Davis J.M. Basic cell culture (2002), Oxford university press, Oxford
7. Deshane J., Loechel F., Conry R.M., Siegal G.P., King C.R., and Curiel D.T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1 (1994) 332
8. Deshane J., Cabrera G., Grim J.E., Siegal G.P., Pike J., Alvarez R.D., and Curiel D.T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol. 59 (1995) 8
9. Ekerljung L., Steffen A.C., Carlsson J., and Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol. 27 (2006) 201
10. Friedman M., Nordberg E., Hoiden-Guthenberg I., Brismar H., Adams G.P., Nilsson F.Y., Carlsson J., and Stahl S. Phage display selection of affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 4 (2007) 189
11. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16 (1997) 1647
12. Gronwall C., Jonsson A., Lindstrom S., Gunneriusson E., Stahl S., and Herne N. Selection and characterization of affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 128 (2007) 162
13. Gunneriusson E., Nord K., Uhlen M., and Nygren P. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng. 12 (1999) 873
14. Hu Y.P., Venkateswarlu S., Sergina N., Howell G., St Clair P., Humphrey L.E., Li W., Hauser J., Zborowska E., Willson J.K., and Brattain M.G. Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells. J. Biol. Chem. 280 (2005) 27383
15. Jannot C.B., Beerli R.R., Mason S., Gullick W.J., and Hynes N.E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13 (1996) 275
16. Klein C., Bueler H., and Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191 (2000) 1699
17. Lundberg E., Hoiden-Guthenberg I., Larsson B., Uhlen M., and Graslund T. Site-specifically conjugated anti-HER2 affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J. Immunol. Methods 319 (2007) 53
18. Munro S., and Pelham H.R. A C-terminal signal prevents secretion of luminal ER proteins. Cell 48 (1987) 899
19. Nord K., Nilsson J., Nilsson B., Uhlen M., and Nygren P.A. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 8 (1995) 601
20. Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlen M., and Nygren P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 15 (1997) 772
21. Nord K., Nord O., Uhlen M., Kelley B., Ljungqvist C., and Nygren P.A. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur. J. Biochem. 268 (2001) 4269
22. Nygren P.A., and Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods 290 (2004) 3
23. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., Widstrom C., Carlsson J., Tolmachev V., Stahl S., and Nilsson F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006) 4339
24. Paganetti P., Calanca V., Galli C., Stefani M., and Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J. Cell Biol. 168 (2005) 863
25. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8392
26. Pelham H.R. The dynamic organisation of the secretory pathway. Cell Struct. Funct. 21 (1996) 413
27. Ronnmark J., Gronlund H., Uhlen M., and Nygren P.A. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. Eur. J. Biochem. 269 (2002) 2647
28. Sandstrom K., Xu Z., Forsberg G., and Nygren P.A. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng. 16 (2003) 691
29. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177
30. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707
31. Steinberger P., Andris-Widhopf J., Buhler B., Torbett B.E., and Barbas III C.F. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 805
32. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandstrom M., Rosik D., Carlsson J., Lundqvist H., Wennborg A., and Nilsson F.Y. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 67 (2007) 2773
33. Wikman M., Steffen A.C., Gunneriusson E., Tolmachev V., Adams G.P., Carlsson J., and Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 17 (2004) 455
34. Wikman M., Rowcliffe E., Friedman M., Henning P., Lindholm L., Olofsson S., and Stahl S. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnol. Appl. Biochem. 45 (2006) 93
35. Yeon C.H., and Pegram M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23 (2005) 391